Table 1.
Characteristics of locally advanced ESCC patients enrolled in this study (n = 547).
| Clinicopathologic variable | Total (N) | Percentage (%) | |
|---|---|---|---|
| Gender | |||
| Male | 382 | 69.8% | |
| Female | 165 | 30.2% | |
| Age (years) | |||
| <65 | 236 | 43.1% | |
| ≥65 | 311 | 56.9% | |
| Weight loss | |||
| Yes | 255 | 46.6% | |
| No | 292 | 53.4% | |
| Tumor location | |||
| Cervical | 43 | 7.9% | |
| Upper thoracic | 152 | 27.8% | |
| Middle thoracic | 285 | 52.1% | |
| Lower thoracic | 67 | 12.2% | |
| RT dose (Gy) | |||
| ≤61.5 | 438 | 80.1% | |
| >61.5 | 109 | 19.9% | |
| Chemotherapy | |||
| Yes | 384 | 70.2% | |
| No | 163 | 29.8% | |
| Targeted therapy | |||
| Yes | 44 | 8.0% | |
| No | 503 | 92.0% | |
| Tumor length (cm) | |||
| <5.5 | 316 | 57.8% | |
| ≥5.5 | 231 | 42.2% | |
| Tumor thickness (cm) | |||
| <1.5 | 241 | 44.1% | |
| ≥1.5 | 306 | 55.9% | |
| T stage | |||
| T2 | 32 | 5.9% | |
| T3 | 294 | 53.7% | |
| T4 | 221 | 40.4% | |
| N stage | |||
| N0 | 165 | 30.2% | |
| N1 | 207 | 37.8% | |
| N2 | 140 | 25.6% | |
| N3 | 35 | 6.4% | |
| TNM stage | |||
| Stage II | 129 | 23.6% | |
| Stage III | 173 | 31.6% | |
| Stage IV | 245 | 44.8% | |
| PNI | |||
| <47 | 280 | 51.2% | |
| ≥47 | 267 | 48.8% | |
| LMR | |||
| <10.8 | 114 | 20.8% | |
| ≥10.8 | 433 | 79.2% | |
| NLR | |||
| <1.71 | 173 | 31.6% | |
| ≥1.71 | 374 | 68.4% | |
| PLR | |||
| <136.3 | 283 | 51.7% | |
| ≥136.3 | 264 | 48.3% | |
| SII | |||
| <633.9 | 359 | 65.6% | |
| ≥633.9 | 188 | 34.4% | |
| RE | |||
| grade0 | 74 | 13.5% | |
| grade1 | 241 | 44.1% | |
| grade2 | 172 | 31.4% | |
| grade3 | 51 | 9.3% | |
| grade4 | 9 | 1.6% |
ESCC, esophageal squamous cell carcinoma; RT, radiotherapy; PNI, prognostic-nutrition index; LMR, lymphocyte-monocyte ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelets-lymphocyte ratio; SII, systemic immune-inflammation index; RE, radiation esophagitis.